Ehab L. Atallah, MD

Publications

• Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Asciminib in Clinical Practice in the United States: Real-world asciminib treatment outcomes in CML-CP.

  (Atallah EL, Wei D, Latremouille-Viau D, Rossi C, Damon A, Ferreira G, Guérin A, Jadhav K.) Clin Lymphoma Myeloma Leuk. 2025 Mar;25(3):178-187.e2 PMID: 39426944 SCOPUS ID: 2-s2.0-85206926730 10/20/2024

• Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations.

  (Atallah E, Deininger M.) Drugs. 2025 Jan;85(1):41-50 PMID: 39638957 SCOPUS ID: 2-s2.0-85216136135 12/06/2024

• Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study.

  (Badar T, Narra R, Mims AS, Heckman MG, Shallis RM, Fahad S, Hunter C, Kota V, Othman TA, Jonas B, Desai S, de Camargo Correia GS, Patel A, DuVall AS, Palmisiano N, Curran E, Omer Z, Advani A, Atallah E, Litzow M.) Am J Hematol. 2024 Dec;99(12):2388-2391 PMID: 39253997 SCOPUS ID: 2-s2.0-85203436363 09/10/2024

• Prognostic impact of 'multi-hit' <i>versus</i> 'single-hit' <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.

  (Badar T, Nanaa A, Atallah E, Shallis RM, Craver EC, Li Z, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, Duvall A, Burkart M, Bradshaw D, Abaza Y, Stahl M, Palmisiano N, Murthy GSG, Zeidan AM, Kota V, Patnaik MM, Litzow MR.) Haematologica. 2024 Nov 01;109(11):3533-3542 PMID: 38813716 PMCID: PMC11532685 SCOPUS ID: 2-s2.0-85206113727 05/30/2024

• Transplant or no transplant for TP53 mutated AML.

  (Badar T, Shahzad M, Atallah E, Litzow MR, Kharfan-Dabaja MA.) Oncotarget. 2024 Oct 01;15:674-676 PMID: 39352794 PMCID: PMC11444334 SCOPUS ID: 2-s2.0-85205527584 10/03/2024

• A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.

  (Murthy GSG, Saliba AN, Szabo A, Harrington A, Abedin S, Carlson K, Michaelis L, Runaas L, Baim A, Hinman A, Maldonado-Schmidt S, Venkatachalam A, Flatten KS, Peterson KL, Schneider PA, Litzow M, Kaufmann SH, Atallah E.) Haematologica. 2024 Sep 01;109(9):2864-2872 PMID: 38572562 PMCID: PMC11367232 SCOPUS ID: 2-s2.0-85201433013 04/04/2024

• BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis.

  (Kockerols C, Valk PJM, Dulucq S, Nicolini FE, Mahon FX, Atallah E, Mauro MJ, Radich JP, Bernardi S, Russo D, Farina M, Mori S, Gambacorti-Passerini C, Civettini I, Lu L, Yeung D, Branford S, Colafigli G, Breccia M, Hogenbirk P, van Rosmalen J, Cornelissen JJ, Westerweel PE.) Am J Hematol. 2024 Aug;99(8):1632-1635 PMID: 38769689 SCOPUS ID: 2-s2.0-85193735288 05/21/2024

• Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.

  (Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Liedtke M, Bergeron J, Wood BL, Zhao Y, Wu G, Chang TC, Zhang W, Pratz KW, Dinner SN, Frey N, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, DeAngelo DJ, Patel SB, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave RR, Sharon E, Little RF, Erba HP, Stone RM, Luger SM, Mullighan CG, Tallman MS.) N Engl J Med. 2024 Jul 25;391(4):320-333 PMID: 39047240 PMCID: PMC11334054 SCOPUS ID: 2-s2.0-85199977304 07/26/2024

• Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era of novel therapies using the SEER registry.

  (Muthiah C, Narra R, Atallah E, Juan W, Szabo A, Guru Murthy GS.) Leuk Res. 2024 May;140:107496 PMID: 38547577 SCOPUS ID: 2-s2.0-85188991221 03/29/2024

• Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.

  (Abaza Y, Winer ES, Murthy GSG, Shallis RM, Matthews AH, Badar T, Geramita EM, Kota VK, Swaroop A, Doukas P, Bradshaw D, Helenowski IB, Liu Y, Zhang H, Im A, Litzow MR, Perl AE, Atallah E, Altman JK.) Am J Hematol. 2024 Apr;99(4):606-614 PMID: 38342997 SCOPUS ID: 2-s2.0-85185125850 02/12/2024

• Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

  (Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow MR.) Blood Cancer J. 2024 Feb 20;14(1):32 PMID: 38378617 PMCID: PMC10879201 SCOPUS ID: 2-s2.0-85185454442 02/21/2024

• Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

  (Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SdCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow MR.) Blood Cancer Journal. December 2024;14(1) SCOPUS ID: 2-s2.0-85185454442 12/01/2024